Aetna — Q4 2017 Earnings Presentation
35 slides from Aetna's earnings presentation, Feb 8, 2018
Slide 1: Fourth Quarter 2017 Earnings Conference Call
Fourth Quarter 2017 Earnings Conference Call Larry Merlo President & Chief Executive Officer Dave Denton Executive Vice President & Chief Financial Officer February 8, 2018 Filed by CVS Health Corporation Pursuant to Rule 425 under the Securities Act of 1933 And deemed filed pursuant to Rule 14a-12
Slide 2: No Offer or Solicitation; Additional Information
No Offer or Solicitation This communication is for informational purposes only and not intended to and does not constitute an offer to subscribe for, buy or sell, the solicitation of an offer to subscribe for, buy or sell or an invitation to subscribe for, buy or sell any securities or the solicitat
Slide 3: Participants in the Solicitation; Cautionary Statement
Participants in the Solicitation CVS Health, Aetna, their respective directors and certain of their respective executive officers may be considered participants in the solicitation of proxies in connection with the proposed transaction. Information about the directors and executive officers of CVS H
Slide 4: Forward-looking statements regarding the transaction
Statements in this communication regarding CVS Health and Aetna that are forward-looking, including CVS Health’s and Aetna’s projections as to the closing date for the pending acquisition of Aetna (the “transaction”), the extent of, and the time necessary to obtain, the regulatory approvals required
Slide 5: Additional forward-looking statements
In addition, this communication may contain forward-looking statements regarding CVS Health’s or Aetna’s respective businesses, financial condition and results of operations. These forward-looking statements also involve risks, uncertainties and assumptions, some of which may not be presently known
Slide 6: Forward-looking Statements
Forward-looking Statements This presentation contains forward-looking statements within the meaning of the federal securities laws. These forward-looking statements reflect our current views related to our future financial performance, future events and industry and market conditions. Forward-lookin
Slide 7: Fourth Quarter Business Update
Fourth Quarter Business Update © 2018 CVS Health
Slide 8: Fourth Quarter: Solid Results
Fourth Quarter: Solid Results Q4 2017 Change vs. Q4 2016 Consolidated net revenues $48.4 billion 5.3% Adjusted operating profit $3.2 billion 5.7% Adjusted EBITDA $3.8 billion 4.8% Adjusted EPS $1.92 12.0% Free Cash Flow ($642) million (143%) © 2018 CVS Health
Slide 9: 2017 Provides Foundation for Growth in 2018
2017 Provides Foundation for Growth in 2018 2017 Change vs. 2016 Consolidated net revenues $184.8 billion 4.1% Adjusted operating profit $10.0 billion (5.8%) Adjusted EBITDA $12.4 billion (4.4%) Adjusted EPS $5.90 1.0% Free Cash Flow $6.4 billion (22%) © 2018 CVS Health
Slide 10: PBM Business: 2018 Selling Season Seeing Good Progress
PBM Business: 2018 Selling Season Seeing Good Progress Gross wins of ~ $6.2 billion Net new business of ~ $2.4 billion Does not include any impact from our individual Med D PDP Strong retention rate of ~ 96.5% (1) Welcome season saw service levels reaching record performance 2019 Selling Season $39
Slide 11: PBM Business: Top of Mind for Clients
PBM Business: Top of Mind for Clients Plan designs that effectively lower unit costs and overall health care costs Most common are plans with formularies focused on the highest value drugs Clinical programs such as Transform Diabetes Care and Pharmacy Advisor increasingly central to clients’ benefit
Slide 12: PBM Business: Specialty Pharmacy
PBM Business: Specialty Pharmacy In Q4, specialty revenues increased 9.2%; scripts increased 14.5% Benefited from new product introductions and increased access to limited distribution drugs Revenue moderated by: Lower levels of inflation on specialty drugs Increase in generic dispensing within spec
Slide 13: PBM Business: SilverScript Still Clear Leader in Med D Space
PBM Business: SilverScript Still Clear Leader in Med D Space Another successful enrollment period Including non-captive Med D lives CVS Caremark manages for our health plan clients, we have 13.3 million lives under management Medicare Part D Lives Served by CVS Caremark (1)(2) (millions) January ‘17
Slide 14: Retail/LTC Business: Q4 Pharmacy Revenue and Script Growth
Retail/LTC Business: Q4 Pharmacy Revenue and Script Growth (1) Total same-store sales increased 0.1%, more than 100 bps better than expectations Pharmacy same-store sales increased 0.4% Negative impact of ~ 340 bps due to recent generic introductions Pharmacy same-store prescription volumes increase
Slide 15: Retail/LTC Business: Collaborating With All Payors
Retail/LTC Business: Collaborating With All Payors We will return to healthy script growth, driven in part by our new collaborations with Optum, Cigna, and Express Scripts Collaborations will help patients receive the most from their health benefits while improving their health Believe that being pr
Slide 16: Retail/LTC Business: Q4 Front Store Revenue and Gross Margin
Retail/LTC Business: Q4 Front Store Revenue and Gross Margin Front store comps decreased 0.7% Cold and flu season added 80 bps When cold and flu impact adjusted out, comp improved sequentially Reflects a number of factors, including decision to optimize promotional strategies Reduction in circular p
Slide 17: Retail/LTC Business: Real Estate Update
Retail/LTC Business: Real Estate Update Locations at end of Q3 9,751 Opened 65 Closed (13) Retail locations at end of Q4 2017 9,803 Net new locations 52 Relocations 5 Retail locations with pharmacies 9,755 (1) Including 8,060 CVS Pharmacy stores that operated a pharmacy and 1,695 pharmacies located
Slide 18: Fourth Quarter 2017 Financial Review
Fourth Quarter 2017 Financial Review © 2018 CVS Health
Slide 19: Financial Update: Capital Allocation
Financial Update: Capital Allocation For full-year 2017, generated $6.4 billion in free cash Paid ~ $510 million in dividends in Q4; $2.0 billion in full-year 2017 12-month trailing dividend payout ratio of 30.9% (1) Down slightly due to non-cash tax reform benefit captured in net income during Q4 I
Slide 20: Financial Update: Free Cash Flow and Capex
Financial Update: Free Cash Flow and Capex In Q4, outflow of ($642) million in free cash as we settled the CMS payable associated with the 2016 plan year In 2017, gross capital expenditures of ~ $1.9 billion, about $306 million lower than LY Primarily due to higher spend in 2016 on integration of th
Slide 21: Q4 2017 Income Statement: Earnings per Share
Q4 2017 Income Statement: Earnings per Share Q4 Adjusted EPS of $1.92, at the high end of guidance range Several items open at year-end resolved in our favor, causing our effective tax rate to be lower than forecasted None are individually significant and, where appropriate, are factored into 2018 g
Slide 22: Q4 2017 Income Statement: Revenues: Consolidated, PBM
Q4 2017 Income Statement: Revenues: Consolidated, PBM Consolidated revenues of ~ $48.4 billion, up 5.3% vs. LY PBM revenues of $34.2 billion, up 9.3% vs. LY Growth was 150 bps above the high-end of guidance Year-over-year growth driven by increase in pharmacy network and specialty volume, brand infl
Slide 23: Q4 2017 Income Statement: Revenues: Retail/LTC
Q4 2017 Income Statement: Revenues: Retail/LTC Retail/LTC revenues of $20.9 billion, up 0.3% vs. LY Better than expectations due to stronger-than-expected pharmacy same store sales and script growth and better-than-expected volume in front store Stronger cold and flu season contributed ~ 80 bps to f
Slide 24: Q4 2017 Income Statement: Gross Profit Margin: Consolidated, PBM
Q4 2017 Income Statement: Gross Profit Margin: Consolidated, PBM Consolidated adjusted gross margin of 16.3%, down ~ 30 bps vs. LY, primarily driven by mix shift, as lower-margin PBM is growing faster than Retail/LTC Consolidated adjusted gross profit dollars increased 3.5% PBM gross margin of 5.4%,
Slide 25: Q4 2017 Income Statement: Gross Profit Margin: Retail/LTC
Q4 2017 Income Statement: Gross Profit Margin: Retail/LTC Retail/LTC adjusted gross margin of 30.0%, up ~ 25 bps vs. LY Increase primarily driven by favorability in front store margin and increased generic dispensing, partially offset by continued reimbursement pressure Favorability in front store m
Slide 26: Q4 2017 Income Statement: Operating Expenses and Margin
Q4 2017 Income Statement: Operating Expenses and Margin Consolidated: adjusted operating expenses were 9.7% of revenues …~ 30 bps improvement vs. LY PBM: adjusted operating expenses as percent of sales flat to LY Retail/LTC: adjusted operating expenses as percent of sales increased slightly due to l
Slide 27: Q4 2017 Income Statement: Operating Profit and Margin
Q4 2017 Income Statement: Operating Profit and Margin Consolidated Adjusted operating profit increased 5.7%, in line with expectations Adjusted operating margin of 6.6%, flat vs. LY PBM Operating profit increased 13.5%, in line with expectations Operating margin of 4.3%, up ~ 15 bps vs. LY Retail/LT
Slide 28: Q4 2017 Income Statement: Below-the-line
Q4 2017 Income Statement: Below-the-line Net interest expense of $241 million, ~ $1.5 million lower than LY Adjusted effective tax rate of 38.3%; 38.1% for the year (1) Better than expectations Weighted-average share count of ~ 1.0 billion shares The income tax provision for the three months and yea
Slide 29: 2018 Guidance
2018 Guidance © 2018 CVS Health
Slide 30: Guidance: 2018 Full-year Investment from Tax Reform
Guidance: 2018 Full-year Investment from Tax Reform Updating guidance only to reflect plans for investment of tax reform benefit Reduction in tax expense to yield ~ $1.2 billion in cash benefits, allowing us to make incremental investments in our business Anticipate spending at least half of tax ben
Slide 31: Guidance: 2018 Full-year Enterprise Outlook
Guidance: 2018 Full-year Enterprise Outlook Full-year 2018 Net Revenue Growth 0.75% to 2.50% Enterprise Adjusted Operating Profit Growth (1.5%) to 1.5% Tax Rate ~ 27% Assumptions: Revised from January guidance to reflect $275 million investment of the benefit from tax reform in operating expenses. A
Slide 32: Guidance: 2018 Full-year Segment Outlook
Full-year 2018 Retail/LTC Net Revenue Growth 2.5% to 4.0% Same-Store Sales (1) Same-Store Adjusted Scripts (1) (2) 2.0% to 3.5% 6.0% to 7.0% Operating Profit Change (3) Down low-single digits Pharmacy Services Net Revenue Change 1.5% to 3.5% Total Adjusted Claims (4) 1.91 billion to 1.93 billion Ope
Slide 33: Guidance: 2018 Full-year Below-the-Line
Guidance: 2018 Full-year Below-the-Line Share repurchases suspended for 2018 due to Aetna transaction Expect to use cash to pay down existing debt, continue to pay $2 per share annual dividend and fund purchase of Aetna Expect net interest in range of $2.0 billion to $2.3 billion Net interest on exi
Slide 34: Guidance: 2018 Q1 Enterprise Outlook
Guidance: 2018 Q1 Enterprise Outlook Q1 2018 Net Revenue Growth 1.5% to 3.25% Enterprise Adjusted Operating Profit Growth 0.5% to 4.5% Assumptions: Assume for guidance purposes only, Aetna transaction closes after year-end 2018, given the uncertainty of the timing of the close of the transaction. Br
Slide 35: Guidance: 2018 Q1 Segment Performance
Q1 2018 Retail/LTC Net Revenue Growth 4.0% to 5.5% Same-Store Sales (1) Same-Store Adjusted Scripts (1) (2) 4.0% to 5.5% 7.0% to 8.5% Adjusted Operating Profit Growth Low- to mid-single digits Pharmacy Services Net Revenue Growth 2.0% to 3.75% Operating Profit Growth Flattish to slightly up Guidance